05.05.15
Charlottesville, Va.-based Rivanna Medical, a medical device company developing a platform of ultrasound-based technology, has named John A. Williams as president and CEO. He replaces Will Mauldin, Ph.D., a co-founder of Rivanna who remains as Chairman and Chief Technology Officer of the company.
Rivanna is currently commercializing the Accuro platform, a proprietary imaging product that is U.S> Food and Drug Administration (FDA) 510(k)-cleared for spinal anesthesia guidance and a variety of additional imaging applications, such as diagnostic imaging of the cardiac and abdominal anatomies.
Williams is a proven leader with distinguished success in building and selling publicly and privately held healthcare companies. He is known as a strong strategic and analytical thinker with a track record of developing new technologies to accelerate growth. His turnaround experience coupled with his ability to create and execute a long-term vision has consistently enhanced shareholder value. John has successfully led and exited a public company and has raised in excess of $80 million for the companies he has led.
“Rivanna’s co-founders, Dr. Will Mauldin and Dr. Kevin Owen, have done a phenomenal job of building the company and developing the Accuro platform with relatively minimal funding to date,” said Williams. “There are numerous clinical applications for Accuro, which we believe is a disruptive, game-changing device platform technology. Our initial commercial application of the platform, which is based on automated 3-D navigation, is designed for guiding clinicians to a first-attempt success in administering spinal anesthesia. The Accuro platform has an addressable $1.1 billion U.S. market today. Given the significant unmet clinical need for automated image guidance in general, and the spinal anesthesia market in particular, we look forward to soon being able to fast-forward the U.S. commercialization of Accuro, especially with a strategic partner.”
“We are extremely pleased to welcome John Williams to Rivanna,” said Mauldin. “Certainly, his outstanding track record of raising funds for emerging companies bodes well for Rivanna, as we step up our efforts to commercialize the first FDA-cleared product from the Accuro platform—designed to facilitate spinal anesthesia guidance with real-time 3-D navigation of the lumbar spine.”
Rivanna is currently commercializing the Accuro platform, a proprietary imaging product that is U.S> Food and Drug Administration (FDA) 510(k)-cleared for spinal anesthesia guidance and a variety of additional imaging applications, such as diagnostic imaging of the cardiac and abdominal anatomies.
Williams is a proven leader with distinguished success in building and selling publicly and privately held healthcare companies. He is known as a strong strategic and analytical thinker with a track record of developing new technologies to accelerate growth. His turnaround experience coupled with his ability to create and execute a long-term vision has consistently enhanced shareholder value. John has successfully led and exited a public company and has raised in excess of $80 million for the companies he has led.
“Rivanna’s co-founders, Dr. Will Mauldin and Dr. Kevin Owen, have done a phenomenal job of building the company and developing the Accuro platform with relatively minimal funding to date,” said Williams. “There are numerous clinical applications for Accuro, which we believe is a disruptive, game-changing device platform technology. Our initial commercial application of the platform, which is based on automated 3-D navigation, is designed for guiding clinicians to a first-attempt success in administering spinal anesthesia. The Accuro platform has an addressable $1.1 billion U.S. market today. Given the significant unmet clinical need for automated image guidance in general, and the spinal anesthesia market in particular, we look forward to soon being able to fast-forward the U.S. commercialization of Accuro, especially with a strategic partner.”
“We are extremely pleased to welcome John Williams to Rivanna,” said Mauldin. “Certainly, his outstanding track record of raising funds for emerging companies bodes well for Rivanna, as we step up our efforts to commercialize the first FDA-cleared product from the Accuro platform—designed to facilitate spinal anesthesia guidance with real-time 3-D navigation of the lumbar spine.”